Low Testosterone Symptoms: Drugs That Cause or Treat It

What Low Testosterone Actually Feels Like

Low testosterone, clinically called male hypogonadism, produces a cluster of symptoms that overlap with aging, depression, and metabolic disease. The hallmark complaints are persistent fatigue that sleep does not fix, diminished sex drive, erectile dysfunction, and a gradual loss of lean muscle mass.

Physical Signs

Men with confirmed hypogonadism frequently report increased body fat (especially visceral fat), reduced bone mineral density, and decreased body hair growth. A 2010 Endocrine Society clinical practice guideline describes the physical presentation as "decreased muscle mass, increased body fat, and decreased bone mineral density" when serum total testosterone falls below 300 ng/dL on at least two morning measurements 1.

Neuropsychiatric Symptoms

Mood disturbance is common. A cross-sectional analysis within the European Male Ageing Study (EMAS, N=3,369) found that men in the lowest testosterone tertile had significantly higher rates of depressive symptoms and poor concentration compared with eugonadal controls 2. Brain fog, irritability, and impaired short-term memory appear repeatedly in clinical cohorts, though they are harder to quantify on standardized scales.

Sexual Dysfunction

Loss of morning erections, reduced ejaculate volume, and low spontaneous sexual thoughts tend to precede erectile dysfunction. The Massachusetts Male Aging Study followed 1,709 men over roughly 9 years and reported that each 1-standard-deviation decrease in total testosterone was associated with a measurable decline in sexual function scores 3.

Not every man with a testosterone level of 280 ng/dL will feel symptomatic. Symptom burden varies by androgen receptor sensitivity, SHBG levels, and free testosterone fraction.

Drugs That Lower Testosterone

Several widely prescribed drug classes suppress the hypothalamic-pituitary-gonadal (HPG) axis, reduce testicular production, or increase SHBG enough to drop bioavailable testosterone into the hypogonadal range. This is called drug-induced hypogonadism, and it is more common than most clinicians recognize.

Opioids

Opioid-induced androgen deficiency (OPIAD) is the single most prevalent medication-related cause of low testosterone. A 2013 systematic review found that chronic opioid therapy lowered testosterone levels in 69% to 90% of men taking long-acting formulations 4. Methadone, morphine sustained-release, and oxycodone extended-release carry the highest risk. The mechanism involves direct suppression of GnRH pulsatility at the hypothalamic level.

Glucocorticoids

Prednisone, dexamethasone, and other systemic corticosteroids inhibit both GnRH and LH secretion. A study published in the Journal of Clinical Endocrinology & Metabolism reported that men receiving prednisone at doses of 10 mg/day or higher for more than 3 months had significantly suppressed total and free testosterone compared with matched controls 5. Even inhaled corticosteroids at high doses (e.g., fluticasone 1,000 mcg/day) may have a measurable, though smaller, effect.

Other Culprits

These medications carry documented testosterone-lowering effects:

• Ketoconazole (systemic): directly inhibits adrenal and testicular steroidogenesis. Used intentionally at high doses to suppress androgens in advanced prostate cancer 6.
• Spironolactone: blocks androgen receptors and reduces testosterone synthesis. Common in heart failure and acne treatment.
• 5-alpha reductase inhibitors (finasteride, dutasteride): do not lower total testosterone but reduce dihydrotestosterone (DHT), which may cause sexual side effects that mimic hypogonadism 7.
• GnRH agonists (leuprolide, goserelin): produce castrate-level testosterone by design. Used in prostate cancer therapy.
• Certain anticonvulsants (carbamazepine, phenytoin): increase SHBG, lowering free testosterone while total testosterone may remain within the reference range.
• Statins: data are mixed, but some observational studies suggest a modest reduction. A 2013 meta-analysis of 11 trials found no clinically meaningful change in total testosterone with statin therapy 8.

If you developed symptoms of low testosterone after starting a new medication, your clinician should measure morning total testosterone before and, ideally, after a trial medication adjustment.

Testosterone Replacement Therapy: The Standard Treatment

When hypogonadism is confirmed by two low morning testosterone values plus consistent symptoms, testosterone replacement therapy (TRT) is the most direct pharmacologic intervention. The 2018 American Urological Association (AUA) guideline recommends TRT for men with total testosterone below 300 ng/dL and unambiguous symptoms, after ruling out reversible causes 9.

Injectable Testosterone

Testosterone cypionate and testosterone enanthate remain the most commonly prescribed formulations in the United States. Standard dosing ranges from 100 to 200 mg intramuscularly or subcutaneously every 7 to 14 days. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies enrolling 790 men aged 65 and older with testosterone below 275 ng/dL, showed that 1 year of testosterone gel improved sexual function, walking distance, and mood compared with placebo 10.

Topical Formulations

Testosterone gels (AndroGel 1%, Testim 1%) and patches (Androderm) offer daily application without injections. Gels produce more stable serum levels but carry a transference risk to partners and children through skin contact. The FDA requires a boxed warning about secondary exposure for all topical testosterone products.

Oral and Nasal Options

Jatenzo (testosterone undecanoate capsules) received FDA approval in 2019 as the first oral testosterone for hypogonadism that bypasses hepatic first-pass metabolism via lymphatic absorption. Natesto, a nasal testosterone gel applied three times daily, provides another needle-free route, though adherence is challenging for many patients.

Monitoring on TRT

The Endocrine Society guideline recommends checking hematocrit, PSA, liver function, and a lipid panel at baseline, then at 3 to 6 months, then annually 1. Hematocrit above 54% warrants dose reduction, temporary cessation, or therapeutic phlebotomy. PSA should be evaluated in the context of the patient's age-specific reference range and velocity.

Fertility-Preserving Alternatives to TRT

Exogenous testosterone suppresses intratesticular testosterone and gonadotropins, reducing sperm counts to azoospermic or severely oligospermic levels in most men within 3 to 6 months. Men who want to preserve fertility need a different pharmacologic approach.

Clomiphene Citrate

Clomiphene citrate, a selective estrogen receptor modulator (SERM), blocks estrogen feedback at the hypothalamus, increasing GnRH pulsatility and, in turn, LH and FSH. A retrospective study of 86 hypogonadal men treated with clomiphene citrate 25 to 50 mg daily found that mean total testosterone increased from 228 ng/dL to 612 ng/dL after a median of 19 months, with maintained or improved semen parameters 11. Clomiphene is not FDA-approved for male hypogonadism and is used off-label.

Enclomiphene

Enclomiphene is the trans-isomer of clomiphene, currently under investigation as a potentially cleaner pharmacologic option with fewer estrogenic side effects. Phase 2 data showed enclomiphene 25 mg daily raised testosterone to eugonadal levels while preserving sperm counts, but it has not yet received FDA approval for this indication 12.

Human Chorionic Gonadotropin (hCG)

HCG acts as an LH analog, stimulating Leydig cells directly. It is commonly used alongside TRT at doses of 500 to 1,000 IU two to three times per week to maintain intratesticular testosterone and spermatogenesis. A 2005 study found that concurrent hCG (500 IU every other day) maintained intratesticular testosterone levels during exogenous testosterone administration 13.

When Drug-Induced Low Testosterone Is Reversible

Not all drug-induced hypogonadism requires TRT. In many cases, modifying or discontinuing the offending medication restores normal HPG axis function.

Opioid Reduction and Rotation

For men on chronic opioid therapy, dose reduction or rotation to buprenorphine (a partial agonist with less gonadal suppression) can improve testosterone levels. A prospective study of men switched from full agonist opioids to buprenorphine found that 17 of 19 participants had testosterone recovery into the normal range within 12 months 14.

Glucocorticoid Tapering

Steroid-induced hypogonadism typically reverses within weeks to months of dose reduction. There is no fixed timeline; recovery depends on dose, duration of use, and individual HPG axis resilience. For men who cannot reduce corticosteroids (e.g., organ transplant recipients), TRT or clomiphene may be necessary as bridge therapy.

Reassessment Protocol

The AUA guideline recommends re-measuring testosterone 3 months after discontinuing a suspected offending drug 9. If levels remain below 300 ng/dL on two separate morning draws, the hypogonadism is likely multifactorial and warrants treatment regardless of the medication history.

Beyond Medications: Lifestyle Factors That Compound Drug Effects

Drug-induced testosterone suppression rarely acts in isolation. Obesity, poor sleep, excessive alcohol intake, and chronic stress each independently lower testosterone, and their effects stack with pharmacologic suppression.

Obesity and Aromatization

Adipose tissue contains aromatase, which converts testosterone to estradiol. Men with a BMI above 30 have, on average, 30% lower total testosterone than normal-weight peers. In the Hypogonadism in Males (HIM) study (N=2,162), the prevalence of hypogonadism was 40.4% in obese men compared with 26% in men with a normal BMI 15.

Sleep Deprivation

A controlled crossover study published in JAMA found that restricting sleep to 5 hours per night for one week decreased daytime testosterone levels by 10% to 15% in healthy young men 16. Obstructive sleep apnea exerts a similar and additive effect.

Resistance Training and Weight Loss

Weight loss of 5% to 10% of body weight has been shown to increase total testosterone by approximately 50 to 100 ng/dL in obese men, even without pharmacologic intervention. Progressive resistance training provides an independent boost through acute post-exercise testosterone elevations and chronic improvements in body composition.

A clinician evaluating a man on opioids for chronic pain, for example, should address sleep hygiene, screen for sleep apnea, and recommend structured exercise before concluding that TRT is the only path forward.

Emerging Drug Therapies on the Horizon

The pipeline for hypogonadism treatment includes several compounds in late-stage clinical development.

Oral Testosterone Undecanoate (Kyzatrex)

Kyzatrex received FDA approval in 2022 as a second oral testosterone option using a proprietary lipid formulation. It offers twice-daily dosing with food and avoids the liver toxicity associated with older methyltestosterone formulations. Post-marketing data on cardiovascular outcomes are still accumulating.

Dimethandrolone Undecanoate (DMAU)

DMAU is a dual androgen/progestin under investigation as both a male contraceptive and a potential hypogonadism therapy. A phase 1 study in 100 healthy men showed dose-dependent testosterone suppression with DMAU, confirming its pharmacologic activity, though its use as a testosterone replacement (at lower doses) remains theoretical 17.

Selective Androgen Receptor Modulators (SARMs)

Compounds like enobosarm (GTx-024) have shown tissue-selective anabolic effects in phase 2 trials for cancer cachexia. Their role in primary hypogonadism is undefined, and the Endocrine Society explicitly advises against using SARMs outside of approved clinical trials due to safety and regulatory concerns 1.

How Diagnosis Works: Testing and Interpretation

Two morning total testosterone measurements below 300 ng/dL, drawn between 7:00 a.m. And 10:00 a.m. (when diurnal secretion peaks), confirm the biochemical diagnosis per the 2018 AUA guideline 9.

Additional Lab Work

Free testosterone (calculated via equilibrium dialysis or the Vermeulen equation), SHBG, LH, FSH, prolactin, and a complete metabolic panel should be part of the initial workup. LH and FSH distinguish primary hypogonadism (testicular failure, elevated gonadotropins) from secondary hypogonadism (pituitary or hypothalamic dysfunction, low or inappropriately normal gonadotropins). Most drug-induced hypogonadism is secondary.

When to Image

If LH and FSH are very low (both <1 mIU/mL) and prolactin is elevated, pituitary MRI is indicated to rule out a prolactinoma or other sellar mass. This scenario is uncommon in drug-induced cases but should not be overlooked.

A testosterone level of 280 ng/dL with an LH of 1.2 mIU/mL in a man on chronic methadone tells a clear story: the opioid is suppressing the HPG axis centrally, and the first intervention should be opioid reassessment, not immediate TRT.